Myelin Oligodendrocyte Glycoprotein (35-55) amide (rat, mouse) trifluoroacetate salt

MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4+ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model[1][2][3].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

The expanded CD4+ T cells are largely specific for the myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide 35-55 (MOG35-55), while clonally expanded CD8+ T cells were non-responsive to myelin peptides or proteins[1].

MOG peptide (35-55) (3 mg/mL for 0.1 mL; s.c.; single dose) results active induction of experimental autoimmune encephalomyelitis (EAE) in mice[2]. MOG peptide (35-55) (200 μg; s.c.; single dose) induces a increasing concentration of the eosinophil chemoattractant eotaxin-1 in the spinal cord in the course of EAE induced in C57BL/6 mice[3]. Animal Model: 129S1/SvImJ, C57BL/6 and C57BL/6 X SJL hybrid[2] Dosage: 3 mg/mL, 0.1 mL per mice; accompanied with CFA and 4 mg/mL Mycobacterium tuberculosis Administration: Subcutaneous injection; single dose Result: Showed the expected signs of experimental autoimmune encephalomyelitis (EAE), which started with tail loss of tonus and continued in an ascending fashion in mice immunized with MOG35-55. Animal Model: C57BL/6 mice (8-12 weeks)[3] Dosage: 200 μg Administration: Subcutaneous injection; single dose; analyzed at pre-onset (day 7 post immunization), onset (day 9-13 post immunization) and peak (day 17-19 post immunization) Result: Increased eosinophil abundance in the spinal cord increases in the course of EAE.